{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:07:53Z","timestamp":1789949273366,"version":"4.0.1"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"5-6","license":[{"start":{"date-parts":[[2016,9,8]],"date-time":"2016-09-08T00:00:00Z","timestamp":1473292800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. of Cardiovasc. Trans. Res."],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s12265-016-9710-4","type":"journal-article","created":{"date-parts":[[2016,9,8]],"date-time":"2016-09-08T12:51:51Z","timestamp":1473339111000},"page":"429-431","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Serial Echocardiographic Characteristics, Novel Biomarkers and Cachexia Development in Patients with Stable Chronic Heart Failure"],"prefix":"10.1007","volume":"9","author":[{"given":"Hanna K.","family":"Gaggin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna M.","family":"Belcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parul U.","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrien E.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"James L.","family":"Januzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,8]]},"reference":[{"issue":"18","key":"9710_CR1","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/j.jacc.2011.03.072","volume":"58","author":"JJL Januzzi","year":"2011","unstructured":"Januzzi, J. J. L., Rehman, S. U., Mohammed, A. A., Bhardwaj, A., Barajas, L., Barajas, J., et al. (2011). Use of amino-terminal Pro\u2013B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. Journal of the American College of Cardiology, 58(18), 1881\u20131889.","journal-title":"Journal of the American College of Cardiology"},{"issue":"6","key":"9710_CR2","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","volume":"27","author":"WJ Evans","year":"2008","unstructured":"Evans, W. J., Morley, J. E., Argiles, J., Bales, C., Baracos, V., Guttridge, D., et al. (2008). Cachexia: a new definition. Clinical Nutrition, 27(6), 793\u2013799.","journal-title":"Clinical Nutrition"},{"issue":"4","key":"9710_CR3","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/ejhf.240","volume":"17","author":"P Rossignol","year":"2015","unstructured":"Rossignol, P., Masson, S., Barlera, S., Girerd, N., Castelnovo, A., Zannad, F., et al. (2015). Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials. European Journal of Heart Failure, 17(4), 424\u2013433.","journal-title":"European Journal of Heart Failure"},{"issue":"4","key":"9710_CR4","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1001\/archinte.167.4.400","volume":"167","author":"A Bayes-Genis","year":"2007","unstructured":"Bayes-Genis, A., Lloyd-Jones, D. M., van Kimmenade, R. R., Lainchbury, J. G., Richards, A. M., Ordonez-Llanos, J., et al. (2007). Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. Archives of Internal Medicine, 167(4), 400\u2013407.","journal-title":"Archives of Internal Medicine"},{"issue":"1","key":"9710_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0167-5273(02)00241-3","volume":"85","author":"PR Kalra","year":"2002","unstructured":"Kalra, P. R., & Tigas, S. (2002). Regulation of lipolysis: natriuretic peptides and the development of cachexia. International Journal of Cardiology, 85(1), 125\u2013132.","journal-title":"International Journal of Cardiology"},{"issue":"9","key":"9710_CR6","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/BF03349021","volume":"19","author":"R Sarzani","year":"1996","unstructured":"Sarzani, R., Dessi-Fulgheri, P., Paci, V. M., Espinosa, E., & Rappelli, A. (1996). Expression of natriuretic peptide receptors in human adipose and other tissues. Journal of Endocrinological Investigation, 19(9), 581\u2013585.","journal-title":"Journal of Endocrinological Investigation"},{"issue":"10","key":"9710_CR7","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1096\/fj.14.10.1345","volume":"14","author":"C Sengenes","year":"2000","unstructured":"Sengenes, C., Berlan, M., De Glisezinski, I., Lafontan, M., & Galitzky, J. (2000). Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB Journal, 14(10), 1345\u20131351.","journal-title":"FASEB Journal"},{"issue":"4","key":"9710_CR8","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S0022-2275(20)31162-7","volume":"42","author":"J Galitzky","year":"2001","unstructured":"Galitzky, J., Sengenes, C., Thalamas, C., Marques, M. A., Senard, J. M., Lafontan, M., et al. (2001). The lipid-mobilizing effect of atrial natriuretic peptide is unrelated to sympathetic nervous system activation or obesity in young men. The Journal of Lipid Research, 42(4), 536\u2013544.","journal-title":"The Journal of Lipid Research"}],"container-title":["Journal of Cardiovascular Translational Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-016-9710-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12265-016-9710-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-016-9710-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T23:03:10Z","timestamp":1657234990000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12265-016-9710-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,8]]},"references-count":8,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["9710"],"URL":"https:\/\/doi.org\/10.1007\/s12265-016-9710-4","relation":{},"ISSN":["1937-5387","1937-5395"],"issn-type":[{"value":"1937-5387","type":"print"},{"value":"1937-5395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,8]]},"assertion":[{"value":"19 May 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standard"}},{"value":"Assays for IL-6, VEGF, and TNF-\u03b1 were performed by Singulex, Inc. The sponsor had no role in design, data collection, analysis, manuscript preparation, interpretation, or decision to submit the manuscript for publication. Dr. Ibrahim is supported by the Dennis and Marilyn Barry Cardiology Fellowship. Dr. Gaggin is supported in part by the Ruth and James Clark Fund for Cardiac Research Innovation, and Dr. Januzzi is supported in part by the Hutter Family Professorship in Cardiology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. Gaggin reports the following disclosures: (1) Roche Diagnostics: research grant, consultancy; (2) Portola: research grant; (3) Amgen: consultancy; (4) American Regent: consultancy; (5) Boston Heart Diagnostics: consultancy; (6) Critical Diagnostics: consultancy; and (7) EchoSense: clinical endpoint committee. Dr. Januzzi reports the following disclosures: (1) Roche Diagnostics: research grants, consultancy; (2) Siemens Diagnostics: research grants; (3) Prevencio: research grants; (4) Singulex: research grants; (5) Critical Diagnostics: consultancy; (6) Sphingotec: consultancy; (7) Philips: consultancy; (8) Cardiorentis: consultancy; (9) Novartis: clinical endpoints committee, consultancy; (10) Boeringer-Ingelheim: clinical endpoints committee, consultancy; and (11) Amgen: data monitoring committee. None of the other authors has disclosures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}